SCHEMBL2432659

SCHEMBL2432659

COc1cc(CC(=O)O)cc(F)c1[N+](=O)[O-]

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.47
GAA P10253 3/20 0.47
TDP1 Q9NUW8 3/20 0.47
TSHR P16473 1/20 0.47
NFKB1 P19838 1/20 0.47
PKM P14618 1/20 0.43
CA5A P35218 1/20 0.42
THRB P10828 1/20 0.41
KDM4E B2RXH2 3/20 0.40
POLB P06746 2/20 0.40
CTDSP1 Q9GZU7 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
LMNA P02545 2/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.38
NPSR1 Q6W5P4 1/20 0.37
HSD17B10 Q99714 1/20 0.37
PTGS1 P23219 1/20 0.37
AKR1C3 P42330 1/20 0.37
AKR1C2 P52895 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5690976 0.90 GAA (0.53) ALDH1A1GAATDP1TSHRNFKB1
SCHEMBL1151055 0.85 CYP1A2 (0.40) GAATDP1TSHRNFKB1THRB
SCHEMBL5691056 0.84 GAA (0.55) ALDH1A1GAATDP1TSHRNFKB1
SCHEMBL2036985 0.84 TTR (0.45) ALDH1A1GAATDP1TSHRPKM
SCHEMBL31285704 0.82 PTGS2 (0.46) ALDH1A1GAATDP1PKMKDM4E
SCHEMBL2031894 0.81 KDM4E (0.42) ALDH1A1GAATDP1TSHRPKM
SCHEMBL2637257 0.79 GRM8 (0.40) ALDH1A1TDP1PKMTHRBKDM4E
SCHEMBL2637258 0.79 GRM8 (0.40) ALDH1A1TDP1PKMTHRBKDM4E
SCHEMBL2303307 0.79 GAA (0.54) ALDH1A1GAATDP1TSHRNFKB1
SCHEMBL30087222 0.78 HTT (0.53) ALDH1A1TDP1TSHRPKMCA5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1346982-B1 VLA-4 INHIBITORS DAIICHI SEIYAKU CO (JP) 2011-09-14 EP disclosed
EP-1346982-B1 VLA-4 INHIBITORS DAIICHI SEIYAKU CO (JP) 2011-09-14 EP disclosed
US-7157487-B2 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-01-02 US disclosed
US-7157487-B2 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-01-02 US disclosed
US-7157487-B2 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-01-02 US disclosed
US-20040110945-A1 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed
EP-1346982-A1 VLA-4 INHIBITORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-09-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110945-A1 Vla-4 inhibitors VCAM1, ITGA1, ITGB4 ALDH1A1 981/4885GAA 3552/4885TDP1 4666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.